Less than 50% of individuals with food allergy have an epinephrine auto-injector. Being prepared with epinephrine auto-injectors is paramount, yet there have been challenges with consistent access to these devices.
Pre-hospital use of epinephrine is low:
- EMS usage of epinephrine to treat anaphylaxis in Canada is only 36%
- Only 21% of children and 7% of adults globally use their auto-injector prior to going to the hospital
Anaphylaxis management issues:
- 25% of first-time reactions occur at school/daycares
- Children who did not receive prompt administration of epinephrine were more than 2x more likely to be admitted to the hospital
We have increased the number of epinephrine auto-injector brands from 1 to 3 to ensure supply access. We are continuously advocating with government for coverage of this life-saving medication.
Yet there are Canadians who cannot get access, and others who do not know how to recognize signs and symptoms or know how to treat anaphylaxis.
![](https://foodallergycanada.ca/wp-content/uploads/Access-to-epinephrine-for-treatment-of-anaphylaxis-1-1024x1024.png)
We need your help to ensure everyone can access life-saving medication and knows how to recognize and treat anaphylaxis.
Learn about our other initiatives:
Education and support
Educating the next generation
Access to accurate ingredient information